A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology

Models that recapitulate the complexity of human tumors are urgently needed to develop more effective cancer therapies. We report a bank of human patient-derived xenografts (PDXs) and matched organoid cultures from tumors that represent the greatest unmet need: endocrine-resistant, treatment-refractory and metastatic breast cancers. We leverage matched PDXs and PDX-derived organoids (PDxO) for drug screening that is feasible and cost-effective with in vivo validation. Moreover, we demonstrate the feasibility of using these models for precision oncology in real time with clinical care in a case of triple-negative breast cancer (TNBC) with early metastatic recurrence. Our results uncovered a Food and Drug…

• UD
  U.S. Department of Defense

  Awards: W81XWH1210077, W81XWH1410417
• AC
  American Cancer Society

  Award: P30CA042014
• BC
  Breast Cancer Research Foundation
• CP
  Cancer Prevention and Research Institute of Texas

  Awards: CA125123, RP170691
• UO
  University of Utah

  Award: P30CA042014
• HC
  Huntsman Cancer Foundation

  Award: P30CA042014
• HC
  Huntsman Cancer Institute

  Award: P30CA042014
• NI
  National Institutes of Health

  Awards: U54CA224076, P30CA042014, NCI R01, CA125123, U24CA224067
• NC
  National Cancer Institute

  Awards: U54CA224076, U24CA224067, NCI-CA125123, CA125123, U01CA217617, P30CA042014